199 related articles for article (PubMed ID: 32495405)
21. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
22. Reimbursement of licensed cell and gene therapies across the major European healthcare markets.
Jørgensen J; Kefalas P
J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123175
[TBL] [Abstract][Full Text] [Related]
23. Financing and Reimbursement of Approved Advanced Therapies in Several European Countries.
Iglesias-López C; Agustí A; Vallano A; Obach M
Value Health; 2023 Jun; 26(6):841-853. PubMed ID: 36646280
[TBL] [Abstract][Full Text] [Related]
24. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions.
Gonçalves E
Eur J Health Econ; 2022 Mar; 23(2):155-163. PubMed ID: 34106364
[TBL] [Abstract][Full Text] [Related]
25. Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic Review.
Olry de Labry-Lima A; Ponce-Polo A; García-Mochón L; Ortega-Ortega M; Pérez-Troncoso D; Epstein D
Value Health; 2023 Jan; 26(1):138-150. PubMed ID: 36031480
[TBL] [Abstract][Full Text] [Related]
26. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time.
Piemonti L; Scholz H; de Jongh D; Kerr-Conte J; van Apeldoorn A; Shaw JAM; Engelse MA; Bunnik E; Mühlemann M; Pal-Kutas K; Scott WE; Magalon J; Kugelmeier P; Berishvili E
Transpl Int; 2023; 36():11633. PubMed ID: 37822447
[TBL] [Abstract][Full Text] [Related]
27. Pricing and reimbursement mechanisms for advanced therapy medicinal products in 20 countries.
Rejon-Parrilla JC; Espin J; Garner S; Kniazkov S; Epstein D
Front Pharmacol; 2023; 14():1199500. PubMed ID: 38089054
[No Abstract] [Full Text] [Related]
28. Emerging technologies for quality control of cell-based, advanced therapy medicinal products.
Zia S; Pizzuti V; Paris F; Alviano F; Bonsi L; Zattoni A; Reschiglian P; Roda B; Marassi V
J Pharm Biomed Anal; 2024 Aug; 246():116182. PubMed ID: 38772202
[TBL] [Abstract][Full Text] [Related]
29. Health technology assessment for the NHS in England and Wales.
Woods K
Int J Technol Assess Health Care; 2002; 18(2):161-5. PubMed ID: 12053415
[TBL] [Abstract][Full Text] [Related]
30. A pipeline analysis of advanced therapy medicinal products.
Wilkins GC; Lanyi K; Inskip A; Ogunbayo OJ; Brhlikova P; Craig D
Drug Discov Today; 2023 May; 28(5):103549. PubMed ID: 36963609
[TBL] [Abstract][Full Text] [Related]
31. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products.
Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ
Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453
[TBL] [Abstract][Full Text] [Related]
32. What are the Changes in 2023 for Access to Advanced Therapy Medicinal Products (ATMPs) in France?
Bartos B
Eur J Health Law; 2024 Jan; 31(2):187-208. PubMed ID: 38280386
[TBL] [Abstract][Full Text] [Related]
33. Funding breakthrough therapies: A systematic review and recommendation.
Hanna E; Toumi M; Dussart C; Borissov B; Dabbous O; Badora K; Auquier P
Health Policy; 2018 Mar; 122(3):217-229. PubMed ID: 29223847
[TBL] [Abstract][Full Text] [Related]
34. Challenges in the market access of regenerative medicines, and implications for manufacturers and decision-makers: a systematic review.
Qiu T; Pochopień M; Hanna E; Liang S; Wang Y; Han R; Toumi M; Aballéa S
Regen Med; 2022 Mar; 17(3):119-139. PubMed ID: 35042424
[TBL] [Abstract][Full Text] [Related]
35. Barriers for the evaluation of advanced therapy medicines and their translation to clinical practice: Umbrella review.
Aguilera-Cobos L; Rosario-Lozano MP; Ponce-Polo A; Blasco-Amaro JA; Epstein D
Health Policy; 2022 Dec; 126(12):1248-1255. PubMed ID: 36283859
[TBL] [Abstract][Full Text] [Related]
36. Environmental risk assessment of advanced therapies containing genetically modified organisms in the EU.
Whomsley R; Palmi Reig V; Hidalgo-Simon A
Br J Clin Pharmacol; 2021 Jun; 87(6):2450-2458. PubMed ID: 33600022
[TBL] [Abstract][Full Text] [Related]
37. The expanding role of the clinical haematologist in the new world of advanced therapy medicinal products.
Lowdell MW; Thomas A
Br J Haematol; 2017 Jan; 176(1):9-15. PubMed ID: 27748517
[TBL] [Abstract][Full Text] [Related]
38. New Models for the Evaluation of Specialized Medicinal Products: Beyond Conventional Health Technology Assessment and Pricing.
Pani L; Becker K
Clin Drug Investig; 2021 Jun; 41(6):529-537. PubMed ID: 34014509
[TBL] [Abstract][Full Text] [Related]
39. Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine.
Goula A; Gkioka V; Michalopoulos E; Katsimpoulas M; Noutsias M; Sarri EF; Stavropoulos C; Kostakis A
J Clin Med Res; 2020 Dec; 12(12):780-786. PubMed ID: 33447311
[TBL] [Abstract][Full Text] [Related]
40. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
Taylor R
Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
